Natural Products for the Treatment of Chlamydiaceae Infections

Overview

Journal Microorganisms

Specialty Microbiology

Date 2016 Oct 19

PMID 27754466

Citations 10

Authors

Mika A Brown

Michael G Potroz

Seoh-Wei Teh

Nam-Joon Cho

Affiliations

Soon will be listed here.

Abstract

Due to the global prevalence of , exploring studies of diverse antichlamydial compounds is important in the development of effective treatment strategies and global infectious disease management. is the most widely known bacterial family of the order. Among the species in the family , and cause common human diseases, while , , and represent zoonotic threats or are endemic in human food sources. Although chlamydial infections are currently manageable in human populations, chlamydial infections in livestock are endemic and there is significant difficulty achieving effective treatment. To combat the spread of in humans and other hosts, improved methods for treatment and prevention of infection are needed. There exist various studies exploring the potential of natural products for developing new antichlamydial treatment modalities. Polyphenolic compounds can inhibit chlamydial growth by membrane disruption, reestablishment of host cell apoptosis, or improving host immune system detection. Fatty acids, monoglycerides, and lipids can disrupt the cell membranes of infective chlamydial elementary bodies (EBs). Peptides can disrupt the cell membranes of chlamydial EBs, and transferrins can inhibit chlamydial EBs from attachment to and permeation through the membranes of host cells. Cellular metabolites and probiotic bacteria can inhibit chlamydial infection by modulating host immune responses and directly inhibiting chlamydial growth. Finally, early stage clinical trials indicate that polyherbal formulations can be effective in treating chlamydial infections. Herein, we review an important body of literature in the field of antichlamydial research.

Citing Articles

Toxicity Assessment of Resveratrol Liposomes-in-Hydrogel Delivery System by EpiVaginal Tissue Model.

Joraholmen M, Damdimopoulou P, Acharya G, Skalko-Basnet N Pharmaceutics. 2022; 14(6).

PMID: 35745867 PMC: 9231258. DOI: 10.3390/pharmaceutics14061295.

inhibitory effect of Lam. extracts over and on different stages of the chlamydial life cycle.

Entrocassi A, Catalano A, Ouvina A, Wilson E, Lopez P, Rodriguez Fermepin M Heliyon. 2021; 7(5):e06947.

PMID: 34041379 PMC: 8141889. DOI: 10.1016/j.heliyon.2021.e06947.

BC1 Biosurfactant Counteracts the Infectivity of Elementary Bodies.

Foschi C, Parolin C, Giordani B, Morselli S, Luppi B, Vitali B Microorganisms. 2021; 9(5).

PMID: 33946391 PMC: 8147163. DOI: 10.3390/microorganisms9050975.

Inhibitory Activity of Pyrroloisoxazolidine Derivatives against .

Ni M, Xu S, Liu Z, Xue Y, Xie W, Yang S Biomed Res Int. 2021; 2021:8889247.

PMID: 33791384 PMC: 7984888. DOI: 10.1155/2021/8889247.

Liposomes-In-Hydrogel Delivery System Enhances the Potential of Resveratrol in Combating Vaginal Chlamydia Infection.

Joraholmen M, Johannessen M, Gravningen K, Puolakkainen M, Acharya G, Basnet P Pharmaceutics. 2020; 12(12).

PMID: 33322392 PMC: 7764002. DOI: 10.3390/pharmaceutics12121203.

References

Salin O, Alakurtti S, Pohjala L, Siiskonen A, Maass V, Maass M . Inhibitory effect of the natural product betulin and its derivatives against the intracellular bacterium Chlamydia pneumoniae. Biochem Pharmacol. 2010; 80(8):1141-51. DOI: 10.1016/j.bcp.2010.06.051. View

Saberwal G, Nagaraj R . Cell-lytic and antibacterial peptides that act by perturbing the barrier function of membranes: facets of their conformational features, structure-function correlations and membrane-perturbing abilities. Biochim Biophys Acta. 1994; 1197(2):109-31. DOI: 10.1016/0304-4157(94)90002-7. View

Fukushi H, Hirai K . Proposal of Chlamydia pecorum sp. nov. for Chlamydia strains derived from ruminants. Int J Syst Bacteriol. 1992; 42(2):306-8. DOI: 10.1099/00207713-42-2-306. View

Hong K, Schachter J, Moncada J, Zhou Z, House J, Lietman T . Lack of macrolide resistance in Chlamydia trachomatis after mass azithromycin distributions for trachoma. Emerg Infect Dis. 2009; 15(7):1088-90. PMC: 2744222. DOI: 10.3201/eid1507.081563. View

Tormakangas L, Vuorela P, Saario E, Leinonen M, Saikku P, Vuorela H . In vivo treatment of acute Chlamydia pneumoniae infection with the flavonoids quercetin and luteolin and an alkyl gallate, octyl gallate, in a mouse model. Biochem Pharmacol. 2005; 70(8):1222-30. DOI: 10.1016/j.bcp.2005.07.012. View

Isaacs C, Kashyap S, Heird W, Thormar H . Antiviral and antibacterial lipids in human milk and infant formula feeds. Arch Dis Child. 1990; 65(8):861-4. PMC: 1792470. DOI: 10.1136/adc.65.8.861. View

Bechinger B . Structure and functions of channel-forming peptides: magainins, cecropins, melittin and alamethicin. J Membr Biol. 1997; 156(3):197-211. DOI: 10.1007/s002329900201. View

Bebear C, De Barbeyrac B . Genital Chlamydia trachomatis infections. Clin Microbiol Infect. 2009; 15(1):4-10. DOI: 10.1111/j.1469-0691.2008.02647.x. View

Ikigai H, Nakae T, Hara Y, Shimamura T . Bactericidal catechins damage the lipid bilayer. Biochim Biophys Acta. 1993; 1147(1):132-6. DOI: 10.1016/0005-2736(93)90323-r. View

10.

Binet R, Bowlin A, Maurelli A, Rank R . Impact of azithromycin resistance mutations on the virulence and fitness of Chlamydia caviae in guinea pigs. Antimicrob Agents Chemother. 2010; 54(3):1094-101. PMC: 2826001. DOI: 10.1128/AAC.01321-09. View

11.

Saikku P, Wang S, Kleemola M, BRANDER E, Rusanen E, GRAYSTON J . An epidemic of mild pneumonia due to an unusual strain of Chlamydia psittaci. J Infect Dis. 1985; 151(5):832-9. DOI: 10.1093/infdis/151.5.832. View

12.

Yasin B, Pang M, Wagar E . A cumulative experience examining the effect of natural and synthetic antimicrobial peptides vs. Chlamydia trachomatis. J Pept Res. 2004; 64(2):65-71. DOI: 10.1111/j.1399-3011.2004.00172.x. View

13.

Garcia-Montoya I, Cendon T, Arevalo-Gallegos S, Rascon-Cruz Q . Lactoferrin a multiple bioactive protein: an overview. Biochim Biophys Acta. 2011; 1820(3):226-36. PMC: 7127262. DOI: 10.1016/j.bbagen.2011.06.018. View

14.

Nardini P, Nahui Palomino R, Parolin C, Laghi L, Foschi C, Cevenini R . Lactobacillus crispatus inhibits the infectivity of Chlamydia trachomatis elementary bodies, in vitro study. Sci Rep. 2016; 6:29024. PMC: 4926251. DOI: 10.1038/srep29024. View

15.

Hanski L, Genina N, Uvell H, Malinovskaja K, Gylfe A, Laaksonen T . Inhibitory activity of the isoflavone biochanin A on intracellular bacteria of genus Chlamydia and initial development of a buccal formulation. PLoS One. 2014; 9(12):e115115. PMC: 4267780. DOI: 10.1371/journal.pone.0115115. View

16.

Kong F, Tabrizi S, Fairley C, Vodstrcil L, Huston W, Chen M . The efficacy of azithromycin and doxycycline for the treatment of rectal chlamydia infection: a systematic review and meta-analysis. J Antimicrob Chemother. 2015; 70(5):1290-7. DOI: 10.1093/jac/dku574. View

17.

Longbottom D, Coulter L . Animal chlamydioses and zoonotic implications. J Comp Pathol. 2003; 128(4):217-44. DOI: 10.1053/jcpa.2002.0629. View

18.

Harkinezhad T, Geens T, Vanrompay D . Chlamydophila psittaci infections in birds: a review with emphasis on zoonotic consequences. Vet Microbiol. 2008; 135(1-2):68-77. DOI: 10.1016/j.vetmic.2008.09.046. View

19.

Elwell C, Mirrashidi K, Engel J . Chlamydia cell biology and pathogenesis. Nat Rev Microbiol. 2016; 14(6):385-400. PMC: 4886739. DOI: 10.1038/nrmicro.2016.30. View

20.

Alvesalo J, Vuorela H, Tammela P, Leinonen M, Saikku P, Vuorela P . Inhibitory effect of dietary phenolic compounds on Chlamydia pneumoniae in cell cultures. Biochem Pharmacol. 2006; 71(6):735-41. DOI: 10.1016/j.bcp.2005.12.006. View